Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [387]

Synthetic immunotherapy seeks out and destroys tumours in mice with aggressive cancers

Synthetic immunotherapy seeks out and destroys tumours in mice with aggressive cancers

Advanced breast cancer patients denied opportunities to join clinical trials

Advanced breast cancer patients denied opportunities to join clinical trials

Researchers use computer modelling to predict patient tumour responses to radiation therapy

Researchers use computer modelling to predict patient tumour responses to radiation therapy

Antidepressants inhibit cancer growth in mice

Antidepressants inhibit cancer growth in mice

Experimental drug development approach points to better targeted therapies for treatment-resistant leukaemia

Experimental drug development approach points to better targeted therapies for treatment-resistant leukaemia

ESMO 2021: Tyrosine kinase inhibitor prolongs progression-free survival in rare neuroendocrine tumour

ESMO 2021: Tyrosine kinase inhibitor prolongs progression-free survival in rare neuroendocrine tumour

ESMO 2021: Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma

ESMO 2021: Adjuvant immunotherapy prolongs recurrence-free survival in resected stage II B/C melanoma

ESMO 2021: Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

ESMO 2021: Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer

Blood enzyme activity level may indicate which breast cancers are slow growing

Blood enzyme activity level may indicate which breast cancers are slow growing

Immunotherapy after high-dose chemotherapy leads to favorable outcomes in acute myeloid leukaemia

Immunotherapy after high-dose chemotherapy leads to favorable outcomes in acute myeloid leukaemia

More from ecancer